Canaccord Genuity Maintains a 'Buy' on BioMimetic Therapeutics (BMTI); Q3/11 Results Provide Little Clarity Into FDA Mindset for Augment
Go back to Canaccord Genuity Maintains a 'Buy' on BioMimetic Therapeutics (BMTI); Q3/11 Results Provide Little Clarity Into FDA Mindset for Augment| BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) | Delayed: 9.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.49 | 52 Week High | $9.56 | |||
| Open | $9.49 | 52 Week Low | $2.01 | |||
| Day High | $9.49 | P/E | N/A | |||
| Day Low | $9.49 | EPS | $-0.97 | |||
| Volume | 1,100 | |||||
